ACM  >> Vol. 5 No. 2 (June 2015)

    MPV、FIB、UA水平与冠心病的关系及研究进展
    Progress and Relationship between Level of MPV, FIB, UA and Coronary Heart Disease

  • 全文下载: PDF(380KB) HTML   XML   PP.89-94   DOI: 10.12677/ACM.2015.52016  
  • 下载量: 1,234  浏览量: 6,796  

作者:  

贾 梅:内蒙古医科大学病理生理学专业,内蒙古 呼和浩特;
刘志跃:内蒙古医科大学病理学与病理生理学教研室,内蒙古 呼和浩特;
杜秀丽:内蒙古巴彦淖尔市医院,内蒙古 巴彦淖尔

关键词:
冠心病血小板平均体积纤维蛋白原尿酸预测Coronary Heart Disease Mean Platelet Volume Fibrinogen Uric Acid Prediction

摘要:

冠心病严重威胁人类健康,它是多种因素导致的疾病,除了以往的主要危险因素外,近年来大量研究发现,血小板平均体积、血浆纤维蛋白原、血尿酸与冠心病的发生、发展及预后密切相关。MPV是血小板活化的生物学指标,FIB是重要的凝血因子,血尿酸则是重要的炎性因子,通过不同的机制促进血栓形成,参与动脉粥样硬化的发生、发展。联合检测以上三项指标,有可能提高其对冠心病的早期诊断及冠脉病变严重程度的预测价值。本文就血小板平均体积、血浆纤维蛋白原、血尿酸与冠心病的关系及研究进展做一综述。

Coronary heart disease is a serious threat to human health, it is a disease caused by a variety of factors, in addition to main risk factors, in recent years, a large number of studies have found that mean platelet volume, fibrinogen and uric acid is closely related to the occurrence, development and prognosis of coronary heart disease. Mean platelet volume is a biological indicator of platelet activation, fibrinogen is an important clotting factor, uric acid is an important inflammatory cyto-kines, through different mechanisms result in thrombosis, and participate in the occurrence and development of atherosclerosis. Combined detection of three indicators, it is possible to improve its predictive value of early diagnosis and the severity of coronary lesions in coronary heart disease. This paper reviews the progress and relationship between level of mean platelet volume, fibrinogen, uric acid and coronary heart disease.

文章引用:
贾梅, 刘志跃, 杜秀丽. MPV、FIB、UA水平与冠心病的关系及研究进展[J]. 临床医学进展, 2015, 5(2): 89-94. http://dx.doi.org/10.12677/ACM.2015.52016

参考文献

[1] 蔡宗群, 郭舜奇, 郭旭武等 (2014) 急性心肌梗死患者血小板平均体积与临床并发症的相关性. 临床心血管病杂志, 30, 138-141.
[2] Slavka, G., Perkmann, T., Haslacher, H., et al. (2011) Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arteriosclerosis, Thrombosis, and Vas-cular Biology, 31, 1215- 1218.
[3] Jennings, L.K. (2009) Role of platelets in atherothrombosis. American Journal of Cardiology, 103, 4A-10A.
[4] Khode, V., Sindhur, J., Kanbur, D., et al. (2012) Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction: A case control study. Journal of Cardiovascular Disease Research, 3, 272-275.
[5] Chu, S.G., Becker, R.C., Berger, P.B., et al. (2010) Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 8, 148-156.
[6] Lippi, G., Filippozzi, L., Salvagno, G.L., et al. (2009) Increased mean platelet volume in patients with acute coronary syndromes. Archives of Pathology Laboratory Medicine, 133, 1441-1443.
[7] 许文亮, 武越, 惠波等 (2012) 冠心病患者血小板平均体积的变化及相关因素研究. 中国循环杂志, 27, 262-265.
[8] Sansanayudh, N., Anothaisintawee, T., Muntham, D., et al. (2014) Mean platelet volume and coronary artery disease: A systematic review and meta-analysis. International Journal of Cardiology, 175, 433-440.
[9] Coban, E., Ozdogan, M., Yazicioglu, G., et al. (2005) The mean platelet volumein patients with obesity. International Journal of Clinical Practice, 59, 981-982.
[10] Huczek, Z., Kochman, J., Filipiak, K.J., et al. (2005) Mean platelet volum on admission predicts impaired reperfusion and long-termmortal-I tyin acutemyocardial infarction treated with primary percutaneous coronary intervention. Journal of the American College of Cardiology, 46, 284-290.
[11] Yang, A., Pizzulli, L. and Lüderitz, B. (2006) Mean platelet volume as marker of restenosis after percu-taneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thrombosis Research, 117, 371-377.
[12] Yilmaz, M.B., Akin, Y., Biyikoglu, S.F., Guray, U., Kisacik, H.L. and Korkmaz, S. (2004) Left ventricular thombosis is associated with increased mean platelet volume in patients with dilated cardiomyopathy and sinus rhythm. Acta Cardiologica, 59, 41-45.
[13] de Willige, S.U., Standeven, K.F., Philippou1, H. and Ariëns, R.A.S. (2009) The pleiotropic role of the fibrinogen γ’ chain in hemostasis. Blood, 114, 3994-4001.
[14] Keenig, W. (1995) Recent progress in the clinical aspects of fibrinogen. European Heart Journal, 16, 54-59.
[15] 竟雪莹, 祖磊, 桑更生 (2013) 慢性阻塞性肺疾病患者血浆纤维蛋白原与冠心病的相关性研究. 中华全科医学, 10, 1540-1541.
[16] Lominadze, D., Dean, W.L., Tyagi, S.C. and Roberts, A.M. (2010) Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiologica, 198, 1-13.
[17] Fragoso-Lona, J.M., Ramírez-Bello, J., Cruz-Robles, D., Pérez-Méndez, O., de la Peña, A. and Vargas-Alarcón, G. (2009) Pro-inflammatory and anti-inflammatory markers in coronary artery disease and acute ischemic coronary syndrome. Archivos de Cardiología de México, 79, 54-62.
[18] Pacilli, A., De Cosmo, S., Trischitta, V. and Bacci, S. (2013) Role of relationship between HbA1c, fibrinogen and HDL-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus. Atherosclerosis, 228, 247-248.
[19] 王雪青 (1996) 纤维蛋白(原)在动脉粥样硬化发病中的作用及机制. 生理科学进展, 3, 245-248.
[20] Stubbs, M.T., Oschkinat, H., Mayr, I., Huber, R., Angliker, H., Stone, S.R. and Bode, W. (1992) The interaction of thrombin with fibrinogen. A structural basis for its specificity. European Journal of Biochemistry, 206, 187-195.
[21] Lobbes, M.B.I., Kooi, M.E., Lutgens, E., Ruiters, A.W., Passos, V.L., Braat, S.H.J.G., et al. (2010) Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: Towards a multi-biomarker approach. International Journal of Vascular Medicine, 2010, Article ID: 726207.
[22] Kannel, W.B., Wolf, P.A., Castelli, W.P. and D’Agostino, R.B. (1987) Fibrinogen and risk of cardiovascular disease. The Framingham study. Journal of the American Medical Association, 258, 1183-1186.
[23] 胡叶, 智永超, 张芝晶, 刘永华, 王心杰 (2010) 冠心病患者血清纤维蛋白原、高敏C反应蛋白与粥样斑块不稳定性的关系研究. 中国当代医药, 16, 18-20.
[24] 周志健, 代志行, 李晓云, 常晓慧, 李晨玲, 高荣 (2002) 冠心病人止凝血分子标志物指标异常的研究. 中国微循环, 3, 161-162.
[25] Bosevski, M., Kostoska, S., Tosev, S. and Borozanov, V. (2006) Usefulness of D-Dimers and fibrinogen plasma determination in patients with polyvascular disease. Angiologii͡a i sosudistai͡a khirurgii͡a, 12, 9-15.
[26] Tousoulis, D., Papageorgiou, N., Androulakis, E., Briasoulis, A., Antoniades, C. and Stefanadis, C. (2011) Fibrinogen and cardiovascular disease: Genetics and biomarkers. Blood Reviews, 25, 239-245.
[27] 周明权 (2012) 冠心病患者凝血四项及纤维蛋白原多态性分析. 中国实用医药, 5, 70-71.
[28] Gertler, M.M., Garn, S.M. and Levine, S.A. (2012) Serum uric acid in relation to age and physique in health and in coronary heart disease. Annals of Internal Medicine, 34, 1421-1431.
[29] Fang, J. and Alderman, M.H. (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey. Journal of the American Medical Association, 283, 2404-2410.
[30] Krishnan, E., Pandya, B.J., Chung, L., et al. (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Research Therapy, 13, R66.
[31] 党爱民, 刘国仗 (2003) 尿酸和心血管事件. 中华心血管病杂志, 6, 478-480.
[32] Feig, D.I., Kang, D.H. and Johnson, R.J. (2008) Uric acid and cardiovascular risk. The New England Journal of Medicine, 359, 1811-1821.
[33] Culleton, B.F., Larson, M.G., Kannel, W.B. and Levy, D. (1999) Serum uric acid and risk for cardiovascular disease and death: The Framingham heart study. Annals of Internal Medicine, 131, 7-13.
[34] Kanbay, M., Sánchez-Lozada, L.G., Franco, M., Madero, M., Solak, Y., Rodriguez-Iturbe, B., et al. (2011) Microvascular disease and its role in the brain and cardiovascular system: A potential role for uric acid as a cardiorenal toxin. Nephrology Dialysis Transplantation, 26, 430-437.
[35] Zapolski, T., Waciński, P., Kondracki, B., Rychta, E., Buraczyńska, M.J. and Wysokiński, A. (2011) Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiologia Polska, 69, 319-326.
[36] Edwards, N.L. (2009) The role of hyperuricemia in vascular disorders. Current Opinion in Rheumatology, 21, 132-137.
[37] Ruggiero, C., Cherubini, A., Ble, A., Bos, A.J., Maggio, M., Dixit, V.D., et al. (2006) Uric acid and inflammatory markers. European Heart Journal, 27, 1174-1181.
[38] 栾雪静, 李世伟 (2010) 超敏C反应蛋白和血尿酸与心血管疾病的关系. 现代预防医学, 14, 2778-2779.